ADDEX THERAPEUTICS LTD (ADXN) Stock Overview
USA - NASDAQ:ADXN - US00654J2069 - ADR
ADXN Key Statistics, Chart & Performance
The current stock price of ADXN is 9.2 USD. In the past month the price increased by 15.87%. In the past year, price decreased by -6.5%.
ADXN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52 | 794.90B | ||
| JNJ | JOHNSON & JOHNSON | 18.86 | 454.31B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.17 | 264.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.21 | 264.50B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.96 | 256.29B | ||
| MRK | MERCK & CO. INC. | 11.58 | 222.78B | ||
| PFE | PFIZER INC | 8.07 | 155.61B | ||
| SNY | SANOFI-ADR | 11.41 | 124.05B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.75 | 92.51B | ||
| GSK | GSK PLC-SPON ADR | 9.59 | 87.24B | ||
| ZTS | ZOETIS INC | 23.54 | 64.89B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.34 | 46.11B |
Related stock screener links
About ADXN
Company Profile
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 2 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Company Info
ADDEX THERAPEUTICS LTD
Chemin des Mines, 9
Plan-les-Ouates GENEVE CH-1202 CH
CEO: Tim Dyer
Employees: 23
Phone: 41228841555
ADDEX THERAPEUTICS LTD / ADXN FAQ
What is the stock price of ADDEX THERAPEUTICS LTD today?
The current stock price of ADXN is 9.2 USD. The price decreased by -2.02% in the last trading session.
What is the ticker symbol for ADDEX THERAPEUTICS LTD stock?
The exchange symbol of ADDEX THERAPEUTICS LTD is ADXN and it is listed on the Nasdaq exchange.
On which exchange is ADXN stock listed?
ADXN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADDEX THERAPEUTICS LTD stock?
9 analysts have analysed ADXN and the average price target is 7.61 USD. This implies a price decrease of -17.27% is expected in the next year compared to the current price of 9.2. Check the ADDEX THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADDEX THERAPEUTICS LTD worth?
ADDEX THERAPEUTICS LTD (ADXN) has a market capitalization of 9.83M USD. This makes ADXN a Nano Cap stock.
How many employees does ADDEX THERAPEUTICS LTD have?
ADDEX THERAPEUTICS LTD (ADXN) currently has 23 employees.
What are the support and resistance levels for ADDEX THERAPEUTICS LTD (ADXN) stock?
ADDEX THERAPEUTICS LTD (ADXN) has a support level at 8.93 and a resistance level at 9.21. Check the full technical report for a detailed analysis of ADXN support and resistance levels.
Is ADDEX THERAPEUTICS LTD (ADXN) expected to grow?
The Revenue of ADDEX THERAPEUTICS LTD (ADXN) is expected to decline by -21.42% in the next year. Check the estimates tab for more information on the ADXN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADDEX THERAPEUTICS LTD (ADXN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADXN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADXN, evaluating the profitability, health, valuation and growth aspects
- ADDEX THERAPEUTICS LTD (ADXN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADDEX THERAPEUTICS LTD (ADXN) Sales and EPS estimates to see what analysts future expectations are.
- ADDEX THERAPEUTICS LTD (ADXN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADDEX THERAPEUTICS LTD (ADXN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADDEX THERAPEUTICS LTD (ADXN) Stock Chart to make your own analysis
- ADDEX THERAPEUTICS LTD (ADXN) Latest news and press-releases to stay up to date.
Does ADDEX THERAPEUTICS LTD (ADXN) stock pay dividends?
ADXN does not pay a dividend.
When does ADDEX THERAPEUTICS LTD (ADXN) report earnings?
ADDEX THERAPEUTICS LTD (ADXN) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of ADDEX THERAPEUTICS LTD (ADXN)?
The PE ratio for ADDEX THERAPEUTICS LTD (ADXN) is 0.87. This is based on the reported non-GAAP earnings per share of 10.57 and the current share price of 9.2 USD. Check the full fundamental report for a full analysis of the valuation metrics for ADXN.
What is the Short Interest ratio of ADDEX THERAPEUTICS LTD (ADXN) stock?
The outstanding short interest for ADDEX THERAPEUTICS LTD (ADXN) is 10.76% of its float. Check the ownership tab for more information on the ADXN short interest.
ADXN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ADXN. When comparing the yearly performance of all stocks, ADXN turns out to be only a medium performer in the overall market: it outperformed 43.41% of all stocks.
ADXN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADXN. ADXN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ADXN Financial Highlights
Over the last trailing twelve months ADXN reported a non-GAAP Earnings per Share(EPS) of 10.57. The EPS increased by 168.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1410.05% | ||
| ROA | 95.59% | ||
| ROE | 109.29% | ||
| Debt/Equity | 0 |
ADXN Forecast & Estimates
9 analysts have analysed ADXN and the average price target is 7.61 USD. This implies a price decrease of -17.27% is expected in the next year compared to the current price of 9.2.
For the next year, analysts expect an EPS growth of -1500% and a revenue growth -21.42% for ADXN